Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC
NCT07375316Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Dec 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07375316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07375316.